Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine® Approach in Patients with Advanced Solid Cancers

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program.